Journal of the American Society of Nephrology, Vol 4, 214-221, Copyright © 1993 by American Society of Nephrology

REGULAR ARTICLES

Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake

LW Elzinga, S Rosen and WM Bennett
Division of Nephrology and Hypertension, Oregon Health Sciences University, Portland 97201.

In addition to its well-recognized ability to provoke acute renal dysfunction by promoting intense renal vasoconstriction, cyclosporine produces a chronic tubulointerstitial nephropathy characterized by striped interstitial fibrosis in humans. With a model of chronic cyclosporine nephropathy in which striped fibrosis develops in the uninephrectomized salt-depleted rat, the relationship between renal functional impairment and structural changes was studied during cyclosporine treatment and after its withdrawal in order to ascertain the natural history of this lesion. Groups of uninephrectomized rats maintained on a salt-depleted (-NaCl) or salt-replete (+NaCl) diet were treated with cyclosporine, 15 mg/kg per day, or vehicle by sc injection. GFR and morphology were assessed at 14 and 28 days of treatment and at intervals up to 28 days after drug withdrawal. Although GFR was similarly depressed in cyclosporine-treated animals on either diet (P < 0.001 versus vehicle), tubulointerstitial injury was largely confined to cyclosporine-treated rats on the -NaCl diet (P < 0.001 versus cyclosporine/+NaCl and vehicle). At 28 days after the withdrawal of cyclosporine, there was a marked discordance between renal structure and function in the cyclosporine/-NaCl group as GFR returned toward normal (P > 0.05 versus cyclosporine/+NaCl) but prominent tubulointerstitial injury persisted and, in some instances, even progressed (P < 0.001 versus cyclosporine/+NaCl and vehicle). Thus, sodium intake emerges as an important determinant of structural tubulointerstitial changes, whereas reductions in GFR during cyclosporine therapy are equivalent in sodium-depleted or sodium- replete animals.

This article has been cited by other articles:

				N. A. Bobadilla and G. Gamba New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone Am J Physiol Renal Physiol, July 1, 2007; 293(1): F2 - F9. [Abstract] [Full Text] [PDF]

				J. Perez-Rojas, J. A. Blanco, C. Cruz, J. Trujillo, V. S. Vaidya, N. Uribe, J. V. Bonventre, G. Gamba, and N. A. Bobadilla Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity Am J Physiol Renal Physiol, January 1, 2007; 292(1): F131 - F139. [Abstract] [Full Text] [PDF]

				S.-W. Lim, C. Li, B.-K. Sun, K.-H. Han, W.-Y. Kim, Y.-W. Oh, J.-U. Lee, P. F. Kador, M. A. Knepper, J. M. Sands, et al. Long-term treatment with cyclosporine decreases aquaporins and urea transporters in the rat kidney Am J Physiol Renal Physiol, July 1, 2004; 287(1): F139 - F151. [Abstract] [Full Text] [PDF]

				J. P. Rerolle, E. Thervet, D. Anglicheau, F. Desgrandchamps, D. Nochy, A. Janin, S. Fornairon, P. Passa, J. Bedrossian, and C. Legendre Long-term renal allograft outcome after simultaneous kidney and pancreas transplantation Nephrol. Dial. Transplant., May 1, 2002; 17(5): 905 - 909. [Abstract] [Full Text] [PDF]

				D.-H. Kang, Y.-G. Kim, T. F. Andoh, K. L. Gordon, S.-I. Suga, M. Mazzali, J. A. Jefferson, J. Hughes, W. Bennett, G. F. Schreiner, et al. Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor Am J Physiol Renal Physiol, April 1, 2001; 280(4): F727 - F736. [Abstract] [Full Text] [PDF]

				T. Nagasawa and T. Ehara CyA-Mediated Renal Interstitial and Vascular Lesions in the Rat under Low-Sodium Diet Toxicol Pathol, July 1, 2000; 28(4): 518 - 528. [Abstract] [PDF]

				H. Herlitz and B. Lindelow Renal failure following cardiac transplantation Nephrol. Dial. Transplant., March 1, 2000; 15(3): 311 - 314. [Full Text] [PDF]

				F. J. KELLY, S. ANDERSON, M. M. THOMPSON, T. T. OYAMA, T. M. KENNEFICK, C. L. CORLESS, R. J. ROMAN, L. KURTZBERG, B. M. PRATT, and S. R. LEDBETTER Acute and Chronic Renal Effects of Recombinant Human TGF-{beta}2 in the Rat J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1264 - 1273. [Abstract] [Full Text]

				D. W. Johnson, H. J. Saunders, F. J. Johnson, S. O. Huq, M. J. Field, and C. A. Pollock Cyclosporin Exerts a Direct Fibrogenic Effect on Human Tubulointerstitial Cells: Roles of Insulin-Like Growth Factor I, Transforming Growth Factor beta 1, and Platelet-Derived Growth Factor J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 535 - 542. [Abstract] [Full Text]

				E. M.A. Mervaala, A.-K. Pere, L. Lindgren, J. Laakso, T.-L. Teravainen, K. Karjala, H. Vapaatalo, J. Ahonen, and H. Karppanen Effects of Dietary Sodium and Magnesium on Cyclosporin A–Induced Hypertension and Nephrotoxicity in Spontaneously Hypertensive Rats Hypertension, March 1, 1997; 29(3): 822 - 827. [Abstract] [Full Text]

				A. K. Singh, W. M. Bennett, J. F. Burke, J. D. Pirsch, and D. R. Salomon Efficacy and Safety of Cyclosporine in Renal-Transplant Recipients N. Engl. J. Med., December 29, 1994; 331(26): 1777 - 1778. [Full Text]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673